PD-1+ NSCLC Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PD-1+ NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in the PD-1 Non-small cell lung cancer market.

Discover the latest drugs and treatment options in the PD-1+ NSCLC Pipeline. Dive into DelveInsight's comprehensive report today! @ PD-1+ NSCLC Pipeline Outlook [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the PD-1+ NSCLC Pipeline Report

* In August 2025, Genfleet Therapeutics (Shanghai) Inc. announced a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC).
* DelveInsight's PD-1+ NSCLC Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for PD-1+ NSCLC treatment.
* The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
* Promising PD-1+ NSCLC Pipeline Therapies such as AZD2936, Cisplatin, Carboplatin, PF-06801591, AK112, Chidamide, Envafolimab and others.

Stay ahead with the most recent pipeline outlook for PD-1+ NSCLC. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ PD-1+ NSCLC Treatment Drugs [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

PD-1+ NSCLC Emerging Drugs Profile

* Zimberelimab: Arcus Biosciences

Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin's lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin's lymphoma. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. The most advanced study with zimberelimab is in Phase III development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic.

* PM8002: Biotheus

PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations. PM8002 had demonstrated a positive safety profile and encouraging antitumor activity presumably through reduced systemic toxicity by enriching anti-VEGF activity into the tumor microenvironment at ASCO Annual Meeting and ESMO Congress 2023. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of NSCLC.

* RPH075: R-Pharm

R-Pharm's pembrolizumab biosimilar, known as RPH 075, is a monoclonal antibody classified under antineoplastics, antivirals, and immunotherapies, specifically tumor-agnostic therapies. This biosimilar mimics the action of the originator drug, pembrolizumab, by targeting and antagonizing the programmed cell death 1 (PD-1) receptor on T lymphocytes. By blocking the interaction between PD-1 and its ligands, RPH 075 enhances T-cell mediated immune responses against cancer cells, promoting antibody-dependent cell cytotoxicity and providing a potent means to counteract tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of NSCLC.

The PD-1+ NSCLC Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of PD-1+ NSCLC with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1+ NSCLC Treatment.
* PD-1+ NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* PD-1+ NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1+ NSCLC market

Explore groundbreaking therapies and clinical trials in the PD-1+ NSCLC Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New PD-1+ NSCLC Drugs [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

PD-1+ NSCLC Companies

Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.

PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

PD-1+ NSCLC Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Unveil the future of PD-1+ NSCLC Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ PD-1+ NSCLC Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the PD-1+ NSCLC Pipeline Report

* Coverage- Global
* PD-1+ NSCLC Companies- Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
* PD-1+ NSCLC Pipeline Therapies- AZD2936, Cisplatin, Carboplatin, PF-06801591, AK112, Chidamide, Envafolimab and others.
* PD-1+ NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* PD-1+ NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on PD-1+ NSCLC Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ PD-1+ NSCLC Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* PD-1 Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Zimberelimab: Arcus Biosciences
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* RPH075: R-Pharm
* Preclinical Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Collaborations Assessment- Licensing / Partnering / Funding
* PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Unmet Needs
* PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Market Drivers and Barriers
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pd1-nsclc-outlook-report-2025-key-25-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.